Doxycycline as a potential partner of COVID-19 therapies

Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, Alexandre E., Granwehr, Bruno P., Kontoyiannis, Dimitrios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298522/
https://www.ncbi.nlm.nih.gov/pubmed/32566483
http://dx.doi.org/10.1016/j.idcr.2020.e00864
_version_ 1783547224090738688
author Malek, Alexandre E.
Granwehr, Bruno P.
Kontoyiannis, Dimitrios P.
author_facet Malek, Alexandre E.
Granwehr, Bruno P.
Kontoyiannis, Dimitrios P.
author_sort Malek, Alexandre E.
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.
format Online
Article
Text
id pubmed-7298522
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72985222020-06-19 Doxycycline as a potential partner of COVID-19 therapies Malek, Alexandre E. Granwehr, Bruno P. Kontoyiannis, Dimitrios P. IDCases Article Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage. Elsevier 2020-06-06 /pmc/articles/PMC7298522/ /pubmed/32566483 http://dx.doi.org/10.1016/j.idcr.2020.e00864 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Malek, Alexandre E.
Granwehr, Bruno P.
Kontoyiannis, Dimitrios P.
Doxycycline as a potential partner of COVID-19 therapies
title Doxycycline as a potential partner of COVID-19 therapies
title_full Doxycycline as a potential partner of COVID-19 therapies
title_fullStr Doxycycline as a potential partner of COVID-19 therapies
title_full_unstemmed Doxycycline as a potential partner of COVID-19 therapies
title_short Doxycycline as a potential partner of COVID-19 therapies
title_sort doxycycline as a potential partner of covid-19 therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298522/
https://www.ncbi.nlm.nih.gov/pubmed/32566483
http://dx.doi.org/10.1016/j.idcr.2020.e00864
work_keys_str_mv AT malekalexandree doxycyclineasapotentialpartnerofcovid19therapies
AT granwehrbrunop doxycyclineasapotentialpartnerofcovid19therapies
AT kontoyiannisdimitriosp doxycyclineasapotentialpartnerofcovid19therapies

Ejemplares similares